Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Zwick

Podiatrist, Foot & Ankle Surgery Miami, FL Doctor of Podiatric Medicine

NPI 1043217235 CMS profile 318941

1321 Nw 14Th St, Suite 103, Miami, FL 33125

Open in the dashboard

General payments

$108,190

333 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Zwick of Miami, FL is reported in the CMS Open Payments database as having received $108,190 across 333 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $53,932 68
2024 General $23,203 55
2023 General $1,546 38
2022 General $11,729 68
2021 General $4,831 29
2020 General $1,550 19
2019 General $11,400 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Zwick
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Thomas Zwick were reported at $53,932. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Thomas Zwick Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $11,400 $389 $118–$1,406 $163
2020 $1,550 $191 $62–$691 $114
2021 $4,831 $329 $104–$1,341 $132
2022 $11,729 $419 $125–$1,611 $149
2023 $1,546 $377 $128–$1,164 $160
2024 $23,203 $394 $134–$1,168 $164
2025 $53,932 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $97,864 139 payments
  2. Medline Industries, Inc. $3,167 14 payments
  3. Treace Medical Concepts, Inc. $1,117 23 payments
  4. Smith+Nephew, Inc. $985 27 payments
  5. Musculoskeletal Transplant Foundation Inc. $783 4 payments
  6. AbbVie, Inc. $780 25 payments
  7. Arthrex, Inc. $478 11 payments
  8. GRT US Holding, Inc. $419 8 payments
  9. Averitas Pharma Inc. $389 10 payments
  10. Sanara MedTech Inc. $365 10 payments
  11. Other $1,844 62 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $59,503 29 payments
  2. Consulting Fee $28,655 8 payments
  3. Food and Beverage $11,018 259 payments
  4. Travel and Lodging $8,192 35 payments
  5. Honoraria $800 1 payment
  6. Gift $22 1 payment
Products named General payments · program years 2019–2025
  1. PURAPLY WOUND MATRIX $65,475 50 payments
  2. Affinity $60,821 34 payments
  3. APLIGRAF Wound Care $56,588 30 payments
  4. NOVACHOR $56,474 29 payments
  5. NuShield $27,725 14 payments
  6. CYGNUS DUAL $27,239 15 payments
  7. Dermagraft $9,808 15 payments
  8. Apligraf Podiatry $9,793 14 payments
  9. Puraply/Affinity/NuTech $9,793 14 payments
  10. Puraply $9,448 29 payments
  11. Other $11,188 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

390

Median for Podiatry: 160

Drug cost

$68,628

Median for Podiatry: $2,368

Branded share of claims

7.7%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Qutenza Capsaicin/Skin Cleanser Brand 18 $60,830
Ciclopirox Generic 69 $2,830
Econazole Nitrate Generic 30 $1,214
Ketoconazole Generic 65 $1,150
Clobetasol Propionate Generic 17 $797
Mupirocin Generic 92 $566
Ammonium Lactate Generic 11 $302
Pregabalin Generic 18 $286
Ibuprofen Generic 16 $210
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 12 $158

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$162,235

Of which drugs: $15,697

Medicare patients

305

Average age 74

Services billed

1,823

145 women, 160 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Diabetes 60%
Ischemic heart disease 49%
Chronic kidney disease 48%
Depression 43%
Heart failure 39%
Atrial fibrillation 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $65
$65 18 —
NUZYRA
  • Paratek Pharmaceuticals, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

333 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record